HMGCR and neoplasm: Pharmacological inhibition of this pathway by targeting the rate-limiting enzyme HMG-CoA reductase (HMGCR) with statins reduces tumor growth and promotes apoptosis, underscoring the dependency of tumors on MVA pathway activity [19–22].